HealthCare Global Enterprises (HCG) Ventures

HealthCare Global Enterprises Ventures is the corporate venture arm of HCG, India’s leading specialty oncology hospital network, partnering with Anthill Ventures to accelerate emerging tech in oncology and life sciences. Check sizes are typically under $250k at Seed and Series A, signaling that the relationship is fundamentally about pilot-based strategic partnership rather than standard financial venture. Healthcare relevance is concentrated and direct: AI in oncology, clinical decision support for cancer care, diagnostic imaging AI for tumor detection and staging, pharma and therapeutic adjacents, and tech that integrates into oncology workflows at HCG’s network of cancer specialty hospitals across India. Founders building general digital health, consumer wellness, biotech assets pre-clinical, or care delivery outside oncology should look elsewhere. The right founder is a clinically credible, technically capable operator with deep oncology domain expertise, building a product that can be validated inside one of India’s most concentrated oncology networks. HCG Ventures is most useful when the strategic narrative writes itself: the technology genuinely moves a clinical or operational metric inside oncology care, and HCG can be both an anchor commercial customer and a clinical validation partner. Geographic and strategic advantage is unique. HCG operates one of India’s largest oncology networks, with significant patient volume, clinical leadership, and academic relationships, plus the Anthill Ventures partnership that brings broader healthcare investing infrastructure. Best entry is via the HCG innovation team, Anthill Ventures introductions, or a clinical advocate inside HCG. Cold inbound rarely converts because clinical buy-in matters as much as financial diligence. Lead the pitch with the oncology problem, the operational or clinical metric you move, the pilot design, and the regulatory pathway under CDSCO and FDA where relevant. Be explicit about DPDP posture, model validation, and clinical performance monitoring in production. Caveats: small check sizes mean HCG Ventures is rarely a sole lead, so founders need a Seed syndicate that can sustain the company beyond the strategic relationship. Negotiate exclusivity, MFN, and data-use language carefully, especially given the partnership structure with Anthill, since the dual-investor dynamic adds complexity. Ask the fund about reserves, prorata behavior, and which Seed and Series A leads have followed it into oncology portfolio companies. Reference checks with current portfolio CEOs on whether the strategic value translated commercially are essential. Used appropriately, HCG Ventures is one of the most credible Indian oncology-strategic partners for clinical AI and oncology-tech founders; for non-oncology healthcare founders, it is a poor fit.